A decision on extended colorectal surgery for CRC should not be based on dMMR immunohistochemistry (loss of MLH1, MSH2, MSH6 or PMS2) and BRAF staining/MLH1 hypermethylation from the preoperative endoscopic biopsy only. This evidence concerns the gene PMS2 and colorectal carcinoma.